Prior authorization sits at the intersection of cost control, clinical decision-making, and patient access. It is also one of the most visible points where healthcare operations feel slower than they should. In Medicare Advantage alone, prior authorization touches nearly every enrollee, with 

 required to obtain approval for at least some services. The responsibility lands heavily on care teams, with physicians handling an average of 43 requests per week and spending about 12 hours completing them.

Patients experience that friction directly. Delayed access affects 

 of patients requesting prior authorization, resulting in 

These are not edge cases. They describe what happens when evidence, policy criteria, and communication move through fragmented systems.

 raise the pressure further, with expedited requests expected to be handled within 72 hours and standard requests within seven calendar days. Denial communication is also expected to become more explicit through electronic means. Public reporting adds a second layer of accountability, with initial scorecard metrics due by March 31, 2026.

This paper argues that winning in this environment requires prior authorization intelligence. That means turning messy clinical inputs into usable evidence, bringing policy criteria into the review flow, and supporting reviewers with decision scaffolding that stays auditable. Coditas has already delivered this for a health tech provider operating large-scale prior authorization workflows. The result was a 

 reviewer throughput, with the pilot moving into production in under 30 days.

The Operational Cost Hiding in Plain Sight

Why Most Fixes Stall After the First Gains

The Promise of Prior Authorization Intelligence

Our Must-Have Prior Authorization Roadmap

Prior authorization was created to protect medical necessity and manage utilization. Those goals still matter. The problem is that the operating model used to achieve them has not kept pace with the complexity of modern care delivery.

Most teams experience prior authorization as an endless stream of requests that rarely arrive in a clean, consistent format. Medical records arrive as structured EMR extracts, scanned documents, PDFs, and sometimes handwritten notes.

Policy documentation is long, scattered across sources, and often hard to navigate at speed.

Reviewers then absorb extensive patient histories and map them to evolving policy rules, which naturally slows throughput and makes scaling difficult.

When leaders ask why the process feels so expensive, the answer is usually framed as staffing or tooling. The reality is more structural. Prior authorization is fundamentally an evidence problem. It is a problem of turning unstructured clinical narratives into structured, defensible decisions repeatedly, under time pressure.

The stakes are visible in outcomes and in rework. Medicare Advantage insurers denied 

 in 2023, representing 6.4% of submissions, and 81.7% of denials were fully or partially overturned on appeal. This level of reversal points to inconsistency in first-pass determinations and poor decision-trail quality.

The issue is easy to underestimate until you translate it into weekly time lost.

When physicians manage an average of 43 prior authorization requests per week and spend roughly 12 hours completing them, it signals a workflow that competes with care delivery for attention. Multiply that across a system, and the opportunity cost becomes self-evident.

Administrative waste compounds the problem. Prior authorization processes still rely heavily on manual channels such as faxes, phone calls, and web portals, and the administrative burden is estimated to account for 

 in US healthcare administrative spending annually. The cost is shared across payers and providers in different ways, but the mechanism is consistent. Staff spend time searching for, reformatting, and re-explaining information.

Patients see the downstream consequences. Delayed access affects 

 of patients requesting prior authorization, and treatment abandonment is reported at 

These are not simply experience issues. They are clinical and financial issues. Delay introduces needless escalation. Abandonment introduces avoidable deterioration and cost.

At this point, many organizations still treat prior authorization as an internal efficiency problem. That framing no longer holds. The same friction that drives cost and delay also creates variability in documentation, decision timelines, and communication quality. Once variability exists at scale, it becomes difficult to defend performance with confidence.

That is why the next phase matters. Regulatory expectations are now converting what used to be operational pain into measurable requirements.

The next phase goes beyond operations to compliance.

Since January 1, 2026, expedited requests are taken care of within three days and standard requests within seven days — a clear constraint on the cycle time. It raises immediate questions for teams already dealing with fragmented inputs and manual review load.

Communication requirements have also tightened. Now payers are required to provide specific reasons for denials through API or other electronic means. For businesses, that translates into a documentation mandate. Decisions need to be explainable in a consistent format, at scale.

Public reporting increases the accountability surface area. CMS will require annual public disclosure of metrics such as approval rates and average turnaround times, with initial metrics due by March 31, 2026. This means organizations are moving into a world where performance and consistency are visible, not just felt internally.

Interoperability requirements will also push the system toward electronic prior authorization. A HL7 FHIR API for prior authorization must be implemented by January 1, 2027.

The industry is expected to save an estimated 

 over 10 years by reducing administrative tasks and processing millions of requests more efficiently. This projection indicates the potential for significant waste to be removed as the operating model modernizes.

Many organizations have already tried to improve prior authorization by adding more staff, building templates, creating new queues, or improving routing logic. These moves usually produce a first round of gains, then the curve flattens.

The reason is that these approaches often optimize surface-level steps without addressing the core evidence and criteria bottleneck.

For a leading health tech provider that Coditas partnered with, the issue was clear. Medical records arrived in multiple formats, including structured EMRs, scanned documents, PDFs, and handwritten notes, making manual extraction inconsistent and labor-intensive. Policy documents were long, complex, and scattered across sources, forcing reviewers to manually locate criteria and increasing the risk of oversight. Reviewers spent time sifting through extensive histories and matching them against changing rules, slowing authorization, and limiting the ability to scale. Even validation was costly, because matching clinical data from EDI transactions with extracted records required rigorous checks, and mistakes triggered rework.

This is why prior authorization intelligence matters. It optimizes operations, moving teams from searching and stitching to reviewing and deciding.

Prior authorization intelligence is not a single feature. It is a set of capabilities that make speed, consistency, and defensibility achievable together.

First, it makes clinical evidence usable.

 Optical character recognition and large language models can extract relevant data from diverse formats and produce structured summaries that organize diagnoses, treatment history, and clinical notes in a chronological order. This creates a consistent review artifact, even when inputs vary.

Second, it makes policy criteria retrievable inside the workflow.

 Using an embedding-based search, policy documents can be linked to diagnosis and procedure codes, with summaries focusing on medical necessity criteria so reviewers see the decision rules without manual searching.

Third, it supports reviewers during the decision-making moment.

 A copilot interface can evaluate patient records against summarized policy criteria, flag eligibility, recommend approvals or denials, and document supporting evidence, while keeping reviewers in full control of final decisions. The outcome is faster decisions with a clearer audit trail.

Fourth, it reduces rework through structured validation.

 Processing requests through EDI integration, with validation workflows matching structured clinical data with incoming requests, reduces mismatches and lowers manual effort.

Finally, it is built to operate at scale.

 Observability for performance tracking and alerting, guardrails for data flows, and strict validation rules for secured API interactions make the system governable in production.

We partnered with a health-tech provider to help streamline complex administrative and clinical workflows throughout the healthcare ecosystem. Their platform managed large-scale prior authorization processes, handling vast medical records and intricate policy documentation.

The operational pressure on their teams was rising. Utilization management reviewers and support staff worked with fragmented data, time-consuming reviews, and inconsistent decision-making. These challenges delayed patient care and reduced operational efficiency.

Coditas designed and implemented a GenAI-powered decision support copilot tailored to prior authorization workflows. The solution combined advanced AI capabilities with healthcare-specific logic to streamline review cycles, structure unstructured data, and support faster, more informed decisions.

Cross-checking EDI data against structured summaries 

, improving accuracy and making decisions more defensible

handled up to 4x additional requests per day

, freeing capacity for complex cases and increasing overall productivity

deployed into production in under 30 days

, supported by a modular architecture that enabled rollout without disrupting clinical workflows

The operational benefit translated into care benefit. With approval delays reduced, patients received treatments sooner, improving continuity and reducing dropouts.

This is the practical promise of prior authorization intelligence. Faster reviews don't have to compromise documentation, and higher throughput doesn't have to reduce clinician control.

Coditas’ Learnings: Must-Have Prior Authorization Roadmap

Collaborating closely with our customers, we have realized that prior authorization modernization works best when it is treated as an evidence system redesign, not a workflow refresh.

 Most delays come from evidence extraction, policy navigation, and validation rework.

 Structured summaries that present a chronological clinical story reduce search time and improve consistency across reviewers.

 Embedding-based retrieval and targeted medical necessity summaries integrate criteria directly into the decision-making process, minimizing the need for manual navigation.

Support reviewers with decision scaffolding

 that documents evidence as decisions are made, while keeping final control with the reviewer.

 through validation workflows tied to EDI integration, matching structured clinical data with requests early in the process.

Finally, build governance into production readiness.

 Observability, type-safe parsing, and strict validation rules create the control layer that enterprises need for audit readiness and operational oversight.

This roadmap aligns naturally with the tighter expectations coming into 2026 and 2027 around turnaround times, electronic denial communication, public reporting, and FHIR-based interoperability.

Our engagement showed what is possible when GenAI is designed around the reviewer workflow, yielding meaningful outcomes that represent an early proof point. But it is important to consider that the pilot ran in a single environment over a limited period, so the same results should not be assumed in all cases.

Prior authorization operations differ widely across organizations based on EMR integration depth, policy complexity, reviewer experience, and overall operational maturity. Impact can also vary by service line, since medical necessity criteria range from straightforward to highly specialized. As the scope expands, broader validation across multiple payer and provider settings, along with service line benchmarks, will help set more realistic expectations and isolate the effect of GenAI from normal learning curves or parallel process changes.

Clinical safety is another area where scale brings new responsibility. The copilot keeps the human reviewer as the final decision-maker and links recommendations to supporting evidence, which is a strong safety baseline. Even so, large language models can still produce incorrect summaries, miss key details, or reflect bias that exists in historical documentation patterns. Over time, there is also a risk that reviewers develop over-reliance on recommendations, especially under throughput pressure. Future iterations should include practical safeguards such as confidence scoring and targeted testing to uncover failure patterns. Routine monitoring should be conducted to detect bias and quality drift, paired with ongoing reviewer enablement to support critical judgment.

Regulatory and audit readiness also becomes more nuanced as deployment expands. The process is designed to support CMS timelines and generate electronic denial explanations with documented rationale. Yet state-specific mandates, audit expectations, and legal defensibility standards can vary, with many organizations aiming to align operations with frameworks such as NCQA utilization management practices. The next step is deeper compliance mapping by state and service line, along with external review of denial rationale quality to keep documentation precise and defensible in disputed cases.

Finally, successful rollout depends as much on governance and operational readiness as it does on technology. The system processes PHI at scale and relies on integrations across EMRs, payer systems, and transaction workflows. That introduces practical considerations around vendor risk, logging and retention discipline, role-based access controls, and incident readiness. Adoption also varies based on change management strength, reviewer training, and legacy system complexity. Future systems should include readiness assessments, more repeatable implementation playbooks, and clearer governance around KPIs, access controls, and audit logging to help organizations scale sustainably.

With prior authorization performance becoming more measurable and visible, the operational load is already showing up in weekly physician time, patient delays, and treatment abandonment. Appeals overturn rates also point to inconsistency and avoidable rework in many systems.

At the same time, the compliance clock is tightening through 2026 and 2027. Faster turnaround requirements begin in 2026, denial communication requirements become more specific through electronic means, and public reporting requirements introduce new external scrutiny. Interoperability requirements push toward FHIR-based electronic prior authorization by 2027.

What do you build so speed improves, decisions remain defensible, and the operating model can scale?

$16B in projected savings over 10 years, tied to administrative reductions

 and processing efficiency, is a useful reference point for the size of the opportunity.

Capturing it requires systems that treat evidence, criteria, and documentation as a connected loop.

Ready to reduce review times and improve decision accuracy? Connect with Coditas at HIMSS26 and discover how our GenAI-powered Prior Authorization solutions can streamline complex care workflows. Click here to know more.

Revolutionizing Prior Authorization with GenAI: A Blueprint for Faster, More Efficient Care Outcomes

Slash prior authorization review time by 70% with GenAI. This blueprint reveals how to achieve faster, more efficient care outcomes while ensuring CMS compliance.

Revolutionizing Prior Authorization with GenAI: A Blueprint for Faster, More Efficient Care Outcomes

Abstract

Follow us on

Want to read further?